Akiyuki Uzawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2037008/publications.pdf

Version: 2024-02-01

		201674	206112
111	2,843	27	48
papers	citations	h-index	g-index

115	115	115	2652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 32-40.	1.9	15
2	Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19. Internal Medicine, 2022, 61, 1071-1076.	0.7	4
3	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. Internal Medicine, 2022, 61, 2785-2787.	0.7	4
4	Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy. Journal of Neuroimmunology, 2022, 365, 577833.	2.3	5
5	Delayed Appearance of Brain Magnetic Resonance Imaging Abnormalities in a Patient with Glial Fibrillary Acidic Protein Astrocytopathy. Internal Medicine, 2022, , .	0.7	0
6	Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clinical and Experimental Immunology, 2021, 203, 366-374.	2.6	57
7	Anti-MOG antibodyâ€“associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	1.9	18
8	Changes in serum complements and their regulators in generalized myasthenia gravis. European Journal of Neurology, 2021, 28, 314-322.	3.3	8
9	Cryptococcal Meningitis in a Fingolimod-Treated Patient. Neurology: Clinical Practice, 2021, 11, e549-e550.	1.6	2
10	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 348-348.	1.9	3
11	Long-term outcomes and prognostic factors in generalized myasthenia gravis. Journal of Neurology, 2021, 268, 3781-3788.	3.6	9
12	Dispersion of mean consecutive differences in singleâ€fiber electromyography increases diagnostic sensitivity for myasthenia gravis. Muscle and Nerve, 2021, 63, 885-889.	2.2	3
13	Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 963-968.	1.9	14
14	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	1.0	6
15	High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model. NeuroReport, 2021, 32, 803-807.	1.2	1
16	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5.5	13
17	Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes. JAMA Neurology, 2021, 78, 853.	9.0	30
18	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. Journal of Neurology, 2021, , 1.	3.6	1

#	Article	IF	Citations
19	Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis. JAMA Neurology, 2021, 78, 1153.	9.0	0
20	High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. Journal of Neuroimmunology, 2021, 358, 577634.	2.3	11
21	Intrathymic Plasmablasts Are Affected in Patients With Myasthenia Gravis With Active Disease. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	6
22	Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis. Scandinavian Journal of Immunology, 2021, , e13122.	2.7	1
23	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 128-129.	3.0	4
24	Safety of tapering tacrolimus dose in patients with wellâ€controlled antiâ€acetylcholine receptor antibodyâ€positive myasthenia gravis. European Journal of Neurology, 2020, 27, 100-104.	3.3	7
25	Frequency and features of myasthenia gravis developing after thymectomy. European Journal of Neurology, 2020, 27, 175-180.	3.3	9
26	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 132-139.	1.9	20
27	Increased serum acetylcholine receptor Î±1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis. Journal of Neuroimmunology, 2020, 339, 577125.	2.3	1
28	Serum antiâ€LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16
29	Severe worsening of myasthenic symptoms after the eculizumab discontinuation. Journal of Neuroimmunology, 2020, 349, 577424.	2.3	5
30	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2020, 202, 239-248.	2.6	6
31	Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study. Clinical and Experimental Immunology, 2020, 202, 321-324.	2.6	3
32	Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 868.	2.4	11
33	Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1189-1194.	1.9	15
34	Longâ€term prognosis of Japanese Lambertâ€“Eaton myasthenic syndrome patients with or without smallâ€cell lung carcinoma. Clinical and Experimental Neuroimmunology, 2020, 11, 131-134.	1.0	1
35	Comparison of brain atrophy in patients with multiple sclerosis treated with firstâ€versus secondâ€generation disease modifying therapy without clinical relapse. European Journal of Neurology, 2020, 27, 2056-2061.	3.3	4
36	Wall-Eyed Bilateral Internuclear Ophthalmoplegia by Ischemic Stroke. Neurologist, 2020, 25, 82-84.	0.7	7

#	Article	IF	Citations
37	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642090420.	3.5	34
38	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. PLoS ONE, 2020, 15, e0224419.	2.5	11
39	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.6	18
40	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	2.3	20
41	Response to â€œLetter to the editors in regard to the article â€˜Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravisâ€™â€• Journal of the Neurological Sciences, 2019, 404, 157-158.	0.6	0
42	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 78-84.	0.6	8
43	Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. Journal of the Neurological Sciences, 2019, 402, 12-15.	0.6	21
44	Response to â€œregarding the article â€˜Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravisâ€™â€• Journal of the Neurological Sciences, 2019, 399, 229.	0.6	0
45	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
46	Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. Journal of the Neurological Sciences, 2019, 396, 8-11.	0.6	22
47	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731875969.	1.0	14
48	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clinical and Experimental Immunology, 2018, 193, 47-54.	2.6	14
49	Soluble CD40 ligand disrupts the bloodâ€“brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2018, 316, 117-120.	2.3	11
50	Case of convulsive seizure developing during electroretinographic recordings: a case report. BMC Neurology, 2018, 18, 52.	1.8	3
51	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. Journal of Neurology, 2018, 265, 1145-1150.	3.6	15
52	Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 513-517.	1.9	19
53	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 385, 64-68.	0.6	10
54	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38

#	Article	IF	Citations
55	Spinal myoclonus selectively affecting the platysma after cervical laminectomy. Neurology, 2018, 91, 45-46.	1.1	1
56	MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 900-900.	1.9	4
57	Adequate tacrolimus concentration for myasthenia gravis treatment. European Journal of Neurology, 2017, 24, 270-275.	3.3	29
58	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. Journal of Neuroimmunology, 2017, 305, 131-134.	2.3	5
59	Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 620-620.	1.9	0
60	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clinica Chimica Acta, 2017, 469, 144-149.	1.1	32
61	Soluble CD40 ligand contributes to bloodâ€“brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2017, 305, 102-107.	2.3	35
62	A clinical predictive score for postoperative myasthenic crisis. Annals of Neurology, 2017, 82, 841-849.	5.3	27
63	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
64	Early fastâ€acting treatment strategy against generalized myasthenia gravis. Muscle and Nerve, 2017, 55, 794-801.	2.2	44
65	A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells. Neurotherapeutics, 2017, 14, 191-198.	4.4	6
66	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on bloodâ€“brain barrier disruption. Multiple Sclerosis Journal, 2017, 23, 1072-1084.	3.0	48
67	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. PLoS ONE, 2017, 12, e0184012.	2.5	10
68	Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. European Journal of Neurology, 2016, 23, 276-281.	3.3	30
69	HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. Journal of the Neurological Sciences, 2016, 363, 116-118.	0.6	21
70	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. Journal of the Neurological Sciences, 2016, 367, 375-379.	0.6	16
71	Changes in inflammatory cytokine networks in myasthenia gravis. Scientific Reports, 2016, 6, 25886.	3.3	37
72	Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurology, 2016, 16, 225.	1.8	22

#	Article	IF	Citations
73	Relationship between damage-associated molecular patterns and cytokines in myasthenia gravis. Clinical and Experimental Neuroimmunology, 2016, 7, 357-360.	1.0	0
74	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 453, 131-133.	1.1	10
75	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2016, 7, 52-58.	1.0	8
76	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Multiple Sclerosis Journal, 2016, 22, 1371-1375.	3.0	9
77	The role of granulocyteâ€macrophage colonyâ€stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. Clinical and Experimental Neuroimmunology, 2015, 6, 70-77.	1.0	0
78	Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. Clinical and Experimental Neuroimmunology, 2015, 6, 299-303.	1.0	1
79	Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 409-412.	1.0	5
80	Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. Journal of Neurology, 2015, 262, 1019-1023.	3.6	23
81	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 147-149.	0.6	14
82	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	2.3	28
83	Serum high mobility group box 1 is upregulated in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 695-697.	1.9	21
84	Epstein-Barr virus persistence and reactivation in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1137-1142.	1.9	31
85	Increased serum peroxiredoxin 5 levels in myasthenia gravis. Journal of Neuroimmunology, 2015, 287, 16-18.	2.3	11
86	Benign neuromyelitis optica is rare in Japanese patients. Multiple Sclerosis Journal, 2015, 21, 1204-1208.	3.0	4
87	Current symptomatology in multiple sclerosis and neuromyelitis optica. European Journal of Neurology, 2015, 22, 299-304.	3.3	25
88	Multiple enhancing brain lesions after discontinuation of fingolimod in a patient with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 52-53.	1.0	0
89	Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2014, 178, 245-252.	2.6	14
90	Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clinical and Experimental Immunology, 2014, 176, 232-237.	2.6	64

#	Article	IF	Citations
91	Neuromyelitis optica: Concept, immunology and treatment. Journal of Clinical Neuroscience, 2014, 21, 12-21.	1.5	48
92	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. Brain Pathology, 2014, 24, 67-73.	4.1	79
93	CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 517-522.	1.9	44
94	Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica Chimica Acta, 2013, 421, 181-183.	1.1	74
95	Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan. Multiple Sclerosis Journal, 2013, 19, 378-379.	3.0	11
96	Role of interleukinâ€6 in the pathogenesis of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 167-172.	1.0	8
97	Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders. Clinical and Experimental Neuroimmunology, 2013, 4, 206-209.	1.0	1
98	Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2013, 172, 37-43.	2.6	44
99	CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 339-340.	1.9	41
100	When is neuromyelitis optica diagnosed after disease onset?. Journal of Neurology, 2012, 259, 1600-1605.	3.6	11
101	Anti-N-methyl d-aspartate-type glutamate receptor antibody-positive limbic encephalitis in a patient with multiple sclerosis. Clinical Neurology and Neurosurgery, 2012, 114, 402-404.	1.4	20
102	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. Journal of Neurology, 2012, 259, 980-981.	3.6	6
103	Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica. Archives of Neurology, 2011, 68, 913.	4.5	40
104	Isolated abducens and facial nerve palsies due to a facial collicular plaque in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 85-86.	1.9	13
105	Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine. Case Reports in Medicine, 2011, 2011, 1-3.	0.7	2
106	Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurology, 2010, 10, 113.	1.8	30
107	Different responses to interferon betaâ€1b treatment in patients with neuromyelitis optica and multiple sclerosis. European Journal of Neurology, 2010, 17, 672-676.	3.3	89
108	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis Journal, 2010, 16, 1443-1452.	3.0	285

#	Article	IF	Citations
109	Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. Journal of Neurology, 2009, 256, 2082-2084.	3.6	104
110	Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. Journal of the Neurological Sciences, 2009, 287, 105-107.	0.6	43
111	Impaired neuromuscular transmission in facial muscles of amyotrophic lateral sclerosis: A singleâ€fiber electromyography study. Neurology and Clinical Neuroscience, 0, , .	0.4	1